Chloroquine

CHEMBL76 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

319.9 g/mol

LogP

4.6

Phase

4

An antimalarial and anti-inflammatory drug that interferes with heme detoxification in plasmodium parasites and modulates lysosomal pH and immune signaling in human cells. It is used to treat and prevent malaria caused by susceptible Plasmodium species and to treat autoimmune conditions including rheumatoid arthritis and lupus. Long-term use requires ophthalmologic monitoring due to the risk of irreversible retinal toxicity.

Molekularmasse

319,9000 g/mol

LogP

4,60

TPSA

28,20 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Migraine Generalized Anxiety Disorder Infectious Disease Melanoma Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Obesity Transplant Medicine Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Malaria HIV/AIDS Hepatitis C Tuberculosis Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12

InChI

InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)

Molecular Formula

C18H26ClN3

HBD / HBA

1 / 3

Rotierbare Bindungen

8

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An antimalarial and anti-inflammatory drug that interferes with heme detoxification in plasmodium parasites and modulates lysosomal pH and immune signaling in human cells. It is used to treat and prevent malaria caused by susceptible Plasmodium species and to treat autoimmune conditions including rheumatoid arthritis and lupus. Long-term use requires ophthalmologic monitoring due to the risk of irreversible retinal toxicity.

Yes, Chloroquine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL76. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2719. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Chloroquine auf PillFYI

Struktur

Schnelldaten

Formel: C18H26ClN3

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.